Navigation Links
Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
Date:2/23/2009

First Full Year of Profitability with GAAP Earnings Per Share of $0.03

2008 Nexavar Net Sales of $678 Million Represents 82% Growth Over 2007

EMERYVILLE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the full year and fourth quarter 2008. For the full year, Onyx recorded net income of $1.9 million, or $0.03 per diluted share, compared with a net loss of $34.2 million, or $0.67 per diluted share, for the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the full year 2008 was $20.7 million, or $0.37 per diluted share, compared to a non-GAAP net loss of $20.0 million, or $0.39 per diluted share, for the same period in 2007. Onyx reported a net loss of $30.2 million, or $0.53 per diluted share, for the fourth quarter 2008, compared to a net loss of $11.7 million, or $0.21 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net loss for the fourth quarter 2008 was $25.2 million, or $0.45 per diluted share, compared to a non-GAAP net loss of $7.8 million, or $0.14 per diluted share, for the same period in 2007. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures are provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.

Global Nexavar net sales grew 82% to $677.8 million for the full year 2008, and grew 41% to $176.5 million for the fourth quarter 2008, compared to $371.7 million and $124.9 million in the same periods in 2007. Onyx, with its collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union and other territories. In accordance with Onyx's collaboration agreement with Bayer, Bayer recognizes all revenue from the sale of Nexavar.

"This has been a year of remarkable growth and advancement for Onyx, as we increased year-over-year sales by 82% and achieved profitability for the year. We've leveraged our successes to invest strategically in the long-term growth potential of the company, creating a rich pipeline with Nexavar and beginning to shape a diversified portfolio beyond Nexavar through strategic but disciplined corporate development activities," stated N. Anthony Coles, M.D., president and chief executive officer of Onyx. "With continued sales growth from Nexavar, a comprehensive development program with near-term value drivers, and a strong financial position, we believe we are well-positioned to drive growing shareholder value in 2009 and the years to come."

Revenue from Collaboration Agreement

As of December 31, 2008 and for earlier periods presented, Onyx has adopted a new financial statement presentation based on guidance from the Financial Accounting Standards Board's Emerging Issues Task Force (EITF) 07-1, Accounting for Collaborative Arrangements. This new presentation changes the classification of amounts included in specific lines in the Statement of Operations, but does not change net income (loss) or net income (loss) per share.

Under this new presentation, the Statement of Operations includes the line item "Revenue from Collaboration Agreement." This line item consists of Onyx's share of the commercial profit generated from the collaboration with Bayer, reimbursement of Onyx's shared marketing costs related to Nexavar and Nexavar royalty revenue. Onyx's 50% share of collaboration research and development expenses is included in the research and development expense line item.

For the full year and fourth quarter 2008, Onyx reported revenue from collaboration agreement of $194.3 million and $49.7 million, respectively, compared to $90.4 million and $26.1 million for the same periods in 2007. The increase in revenue from collaboration agreement between periods is due to an increase in Nexavar revenue recognized by Bayer and higher royalty revenue, partially offset by an increase in commercial expenses related to Nexavar.

Operating Expenses

Onyx recorded research and development expenses of $123.7 million in the full year 2008 and $59.9 million in the fourth quarter 2008, compared to $83.3 million and $27.2 million for the same periods in 2007. Research and development expenses in fourth quarter 2008 include payments made by Onyx to S*BIO Pte Ltd under a development collaboration, option and license agreement and to BTG International Limited under a development and license agreement. Research and development expenses included $3.2 million and $1.1 million of employee stock-based compensation for the full year and fourth quarter 2008, respectively.

Selling, general and administrative expenses were $81.0 million in the full year 2008 and $22.0 million in the fourth quarter 2008, compared to $60.5 million and $16.4 million for the same periods in 2007. Higher selling, general and administrative expenses were primarily due to increased marketing spend and employee-related expenses to support Nexavar, as well as, increased headcount and employee-related expenses to support Onyx's growth. Selling, general and administrative expenses included $15.6 million and $3.9 million of employee stock-based compensation for the full year and fourth quarter 2008, respectively.

Cash, Cash Equivalents and Marketable Securities

At December 31, 2008, cash, cash equivalents, and current and noncurrent marketable securities were $458.0 million, compared to $469.7 million at December 31, 2007. This decrease was primarily due to payments made under our agreements with S*BIO and BTG, partially offset by positive cash flow from operations.

Management Conference Call Today

Onyx will host a teleconference and webcast to provide a general business overview and discuss financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on February 23, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/wt/page/event_calendar

or by dialing 847-413-3238 and using the passcode 23828951. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 23828951 later in the day. The replay will be available through March 23, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other cancers. For more information about Onyx, visit http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding sales trends and commercial activities and the timing, progress and results of clinical development, regulatory filings and actions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of such factors, as well as the company's subsequent quarterly reports on Form 10Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables.)


                               ONYX PHARMACEUTICALS, INC.
                           CONDENSED STATEMENTS OF OPERATIONS
                         (In thousands, except per share amounts)
                                       (unaudited)

                                   Three Months Ended  Twelve Months Ended
                                        December 31,        December 31,
                                   ------------------  ------------------
                                      2008      2007      2008      2007
                                   --------   -------  --------   -------
    Revenue from collaboration
     agreement                      $49,650   $26,101  $194,343   $90,429
    Operating expenses:
      Research and development (1)   59,905    27,226   123,749    83,306
      Selling, general and
       administrative (1)            22,008    16,406    80,994    60,546
                                   --------   -------  --------   -------
    Total operating expenses         81,913    43,632   204,743   143,852
                                   --------   -------  --------   -------
    Loss from operations            (32,263)  (17,531)  (10,400)  (53,423)
    Investment income                 1,999     5,829    12,695    19,256
                                   --------   -------  --------   -------
    Income (loss) before income
     taxes                          (30,264)  (11,702)    2,295   (34,167)
    Provision (benefit) for income
     taxes                              (77)        -       347         -
                                   --------   -------  --------   -------
    Net income (loss)              $(30,187) $(11,702)   $1,948  $(34,167)
                                   ========   =======  ========   =======

    Net income (loss) per share:
      Basic                          $(0.53)   $(0.21)    $0.03    $(0.67)
                                   ========   =======  ========   =======
      Diluted                        $(0.53)   $(0.21)    $0.03    $(0.67)
                                   ========   =======  ========   =======

    Shares used in computing net
     income (loss) per share:
      Basic                          56,430    55,212    55,915    51,177
                                   ========   =======  ========   =======
      Diluted                        56,430    55,212    56,765    51,177
                                   ========   =======  ========   =======

    (1) Includes employee stock-
        based compensation charges
        of:
         Research and development    $1,083      $851    $3,166    $2,897
         Selling, general and
          administrative              3,904     3,010    15,630    11,230
                                   --------   -------  --------   -------
         Total employee stock-based
          compensation               $4,987    $3,861   $18,796   $14,127
                                   ========   =======  ========   =======



                               ONYX PHARMACEUTICALS, INC.
                  CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT
                               (In thousands, unaudited)

                                   Three Months Ended  Twelve Months Ended
                                        December 31,        December 31,
                                   ------------------  ------------------
                                      2008      2007      2008      2007
                                   --------   -------  --------   -------

    Nexavar product revenue, net
    (as recorded by Bayer)         $176,503  $124,919  $677,806  $371,736
                                   ========   =======  ========   =======

    Revenue subject to profit
     sharing (as recorded by
     Bayer)                        $160,874  $124,919  $637,459  $371,736
    Combined cost of goods sold,
     distribution, selling, general
     and administrative expenses     76,593    81,998   298,792   223,682
                                   --------   -------  --------   -------
    Combined commercial
     collaboration profit           $84,281   $42,921  $338,667  $148,054
                                   ========   =======  ========   =======

    Onyx's share of commercial
     collaboration profit           $42,141   $21,460  $169,334   $74,027
    Reimbursement of Onyx's shared
     marketing expenses               6,415     4,641    22,185    16,402
    Royalty revenue                   1,094         -     2,824         -
                                   --------   -------  --------   -------
    Revenue from collaboration
     agreement                      $49,650   $26,101  $194,343   $90,429
                                   ========   =======  ========   =======



                               ONYX PHARMACEUTICALS, INC.
                                CONDENSED BALANCE SHEETS

                                                        (In thousands)
                                                   Dec. 31,         Dec. 31,
                                                     2008             2007
                                                 (unaudited)           (2)
                                                  ---------        ---------
    Assets
    Cash, cash equivalents and marketable
     securities                                    $418,424         $469,650
    Other current assets                             43,635           11,006
                                                  ---------        ---------
    Total current assets                            462,059          480,656
    Property and equipment, net                       3,363            3,146
    Marketable securities, non-current               39,622                -
    Other assets                                      4,723              281
                                                  ---------        ---------
    Total assets                                   $509,767         $484,083
                                                  =========        =========
    Liabilities and stockholders' equity
    Current liabilities                              33,304           11,441
    Advance from collaboration partner, non-current       -           39,234
    Other long-term liabilities                       1,263            1,171
    Stockholders' equity                            475,200          432,237
                                                  ---------        ---------
    Total liabilities and stockholders' equity     $509,767         $484,083
                                                  =========        =========

    (2) Derived from the audited financial statements included in the
        Company's Annual Report on Form 10-K for the year-ended December 31,
        2007.



                                ONYX PHARMACEUTICALS, INC.
                       RECONCILIATION OF GAAP TO NON-GAAP NET INCOME
                          (In thousands, except per share amounts)
                                       (unaudited)

                                   Three Months Ended  Twelve Months Ended
                                        December 31,        December 31,
                                   ------------------  ------------------
                                      2008      2007      2008      2007
                                   --------   -------  --------   -------
    GAAP net income (loss)         $(30,187) $(11,702)   $1,948  $(34,167)
    Non-GAAP adjustments:
      Employee stock-based
       compensation under
       FAS 123R (4)                   4,987     3,861    18,796    14,127
                                   --------   -------  --------   -------
    Non-GAAP net income (loss) (3)   $8,550   $(7,841)  $54,494  $(20,040)
                                   ========   =======  ========  ========

    GAAP diluted net income (loss)
     per share                       $(0.53)   $(0.21)    $0.03    $(0.67)
    Non-GAAP adjustments:
      Employee stock-based
       compensation under
       FAS 123R (4)                    0.08      0.07      0.34      0.28
                                   --------   -------  --------   -------
    Non-GAAP diluted net income
     (loss) per share (3)            $(0.45)   $(0.14)    $0.37    $(0.39)
                                   ========   =======  ========  ========

    Diluted shares                   56,430    55,212    56,765    51,177

    (3) This press release includes the following non-GAAP financial
        measures:  non-GAAP net income (loss) and non-GAAP diluted net income
        (loss) per share.  The foregoing table reconciles these non-GAAP
        measures to the most comparable financial measures calculated in
        accordance with GAAP.

        Our management uses these non-GAAP financial measures to monitor and
        evaluate our operating results and trends on an on-going basis and
        internally for operating, budgeting and financial planning purposes.
        Our management believes the non-GAAP information is useful for
        investors by offering them the ability to better identify trends in
        our business and better understand how management evaluates our
        business. These non-GAAP measures have limitations, however, because
        they do not include all items of income and expense that affect Onyx.
        These non-GAAP financial measures that our management uses are not
        prepared in accordance with, and should not be considered in
        isolation of, or an as alternative to, measurements required by GAAP.

    (4) Employee stock-based compensation under FAS 123R: Our management
        excludes the effects of employee stock-based compensation because of
        varying available valuation methodologies, subjective assumptions and
        the variety of award types; such exclusion facilitates comparisons of
        our operating results to our peer companies.



'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... background. Understanind and choosing the most appropriate instruments for research and understanding the ... research finding. This webinar will focus on innovations in stereo microscopy for brightfield ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
(Date:5/24/2017)... , ... May 24, 2017 ... ... the female reproductive tract in which the endometrial lining of the uterus ... inflammation and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a sought after ... Public Television. “Informed” brings the public important topics from all aspects of life, and ... feet and issues surrounding feet and ankles. , Podiatry is essential to people’s overall ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), ... announced today that its iClinic V12.2 solution has achieved approval from National Center ... introduced PCMH 2017 standards which emphasize team-based care with a significant focus on ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
(Date:5/10/2017)... Ill. , May 10, 2017 Radiology ... today; unfortunately its costs have also spiraled to the ... being sent to radiology than ever before as the ... diagnosis.  For a patient with lower back pain an ... no anatomical reason for pain, resulting in entirely different ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology: